• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Mallinckrodt plc filed SEC Form 8-K: Leadership Update

    11/3/21 4:31:03 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNK alert in real time by email
    8-K
    false 0001567892 0001567892 2021-11-03 2021-11-03

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 3, 2021

     

     

    Mallinckrodt plc

    (Exact name of registrant as specified in its charter)

     

     

     

    Ireland   001-35803   98-1088325
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

    College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland

    (Address of principal executive offices)

    +353 1 6960000 (Registrant’s telephone number, including area code)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act: None

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.02.

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    (b)    On November 3, 2021, it was announced that Kathy A. Schaefer, the Senior Vice President, Finance and Corporate Controller, as well as the principal accounting officer of Mallinckrodt plc (the “Company”) had agreed with the Company to leave effective as of December 17, 2021. Ms. Schaefer’s departure is not a result of any disagreement with the Company’s independent auditors or any member of management on any matter of accounting principles or practices, financial statement disclosure or internal controls.

    (c)    In connection with Ms. Schaefer’s departure, Bryan M. Reasons, the Company’s Executive Vice President and Chief Financial Officer, will be appointed as the Company’s principal accounting officer effective as of December 17, 2021. Mr. Reasons will continue to serve as the Company’s Chief Financial Officer and principal financial officer. Mr. Reasons biographical information is disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 25, 2020 filed with the U.S. Securities and Exchange Commission on March 10, 2021, as amended on April 19, 2021.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    MALLINCKRODT PLC
    (registrant)
    By:  

    /s/ Stephanie D. Miller

      Stephanie D. Miller
      Vice President, General Counsel, International and Corporate Secretary

    Date: November 3, 2021

    Get the next $MNK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MNK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations

    Continuing to Serve Customers and Deliver High-Quality Therapies to Patients Without Interruption; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023. As expected, the Court granted Mallinckrodt approval to ac

    8/30/23 11:54:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations

    Initiates Voluntary Prepackaged Chapter 11 Proceedings with Overwhelming Support of Key Stakeholders, Including 85%+ of First and Second Lien Debtholders Continuing to Operate Normally, Serve Customers and Deliver High-Quality Therapies to Patients Vendors and Suppliers Expected to be Paid in Full in the Ordinary Course DUBLIN, Aug. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has taken the next step to implement the comprehensive financial restructuring plan contemplated by a Restructuring Support Agreement ("RSA") the Company previously entered into with more than 85% of each of th

    8/28/23 12:17:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan

    Agreement Supported by a Substantial Majority of Each of its First and Second Lien Debtholders and Opioid Trust Financial Restructuring Plan to Significantly Reduce Debt, Increase Free Cash Flow Generation, Extend Maturity Runway and Better Position Company for Long-Term Success  Intends to Initiate Voluntary Prepackaged Chapter 11 Proceedings to Implement Plan Continuing to Deliver High-Quality Therapies to Patients and Serve Customers; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 23, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced it has entered into a Restructur

    8/23/23 8:22:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Norton David Y sold $1,334 worth of Ordinary Shares (5,080 units at $0.26), closing all direct ownership in the company

    4 - Mallinckrodt plc (0001567892) (Issuer)

    8/9/21 9:09:30 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: O'Neill Hugh M. sold $537 worth of Ordinary Shares (2,100 units at $0.26), decreasing direct ownership by 3% to 76,856 units

    4 - Mallinckrodt plc (0001567892) (Issuer)

    8/9/21 9:10:08 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: A Kathy Schaefer disposed of $256 worth of Ordinary Shares (675 units at $0.38), decreasing direct ownership by 3% to 22,934 units

    4 - Mallinckrodt plc (0001567892) (Issuer)

    4/5/21 4:24:38 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    SEC Filings

    View All

    Mallinckrodt plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Mallinckrodt plc (0001567892) (Filer)

    11/5/21 6:01:46 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc filed SEC Form 8-K: Leadership Update

    8-K - Mallinckrodt plc (0001567892) (Filer)

    11/3/21 4:31:03 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Mallinckrodt plc

    10-Q - Mallinckrodt plc (0001567892) (Filer)

    11/2/21 6:43:01 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Leadership Updates

    Live Leadership Updates

    View All

    Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer

    DUBLIN, Jan. 12, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr. Peter Richardson, B.Med.Sci., BM, BS, MRCP (UK) has been appointed Executive Vice President and Chief Scientific Officer, effective January 12, 2023. With more than 30 years of research and development experience in the pharmaceutical industry, Dr. Richardson will have executive responsibility for Mallinckrodt's branded research and development (R&D), medical affairs, safety, and regulatory affairs functions. He will serve on the Company's Executive Committee and succeeds Steven Romano, M.D., who departed Mallinckrodt in Dece

    1/12/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Financials

    Live finance-specific insights

    View All

    Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance

    Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net Sales of $424.6 Million; Net Loss of $249.3 Million; Adjusted EBITDA of $123.5 Million; Diluted Loss Per Share of $18.93 and Adjusted Diluted Earnings Per Share of $1.68 Increased Cash on Hand to $480.0 Million and Reduced Exposure to Interest Rate Volatility Through Interest Rate Cap Agreement, Demonstrating Ongoing Focus on Disciplined Balance Sheet Management Reaffirmed 2023 Net Sales and Adjusted EBITDA Guidance Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, May 9, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Malli

    5/9/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt to Report Earnings Results for First Quarter 2023

    DUBLIN, April 24, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that it will report first quarter 2023 earnings results for the period ended March 31, 2023, on Tuesday, May 9, 2023.  A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows: Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BIbe1f9805fe5b4490acd8359f7bdd616dAudio Only Webcast Link (live and replay):https://edge.media-server.com/mmc/p/24fqexpxAt the Mallinckrodt website

    4/24/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 Guidance

    Made Solid Progress on Launch of Terlivaz® with Significant Medical Community Interest Appointed Chief Scientific Officer with Proven Record of Executing Clinical Programs and Advancing Product Development Pipelines Increased Cash on Hand to $409.5 Million, Underscoring Commitment to Strengthening Balance Sheet and Disciplined Approach to Cost Management Fiscal 2023 Guidance for Adjusted EBITDA is $510 Million to $560 Million Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, Feb. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the fourth quarter ended December 30, 2022. 

    2/28/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Mallinckrodt plc (Amendment)

    SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

    11/12/21 2:55:13 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Mallinckrodt plc (Amendment)

    SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

    11/5/21 2:58:50 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Mallinckrodt plc (Amendment)

    SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

    10/22/21 4:48:46 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care